The Einstein-Montefiore Institute for Clinical and Translational Research (ICTR) has evolved over the past two CTSA funding periods, embracing the broad spectrum of clinical and translational (C/T) biomedical research from T1 through T4. We have provided pathways for our clinicians and our integrated healthcare system to expand implementation science, population health, community-engaged research, and clinical trials while also encouraging basic scientists to innovate new therapeutics and diagnostics. This broad involvement with our community and investigators has allowed the CTSA to impact a wide range of research extending from drug design and improving clinical trials management, to training a new research workforce, and to using implementation science for community-engaged and healthcare research. Indeed, the ICTR?s mission?to advance research across the translational spectrum into clinical practice through its integrated infrastructure, innovative training, and institutional co-investment?has evolved in step with that of the National Center for Advancing Translational Sciences. In this application, we will 1) leverage CTSA resources with institutional assets that support state-of-the-art informatics to accelerate the transfer of discoveries to healthcare via an Evidence Generation Framework, and support regulatory streamlining, innovative analytics, and assist with all phases of C/T research; 2) develop the next generation of research workforce and teams, using novel education, training, mentoring, pilot study support, and career development resources that span translational domains; 3) expand collaborations and engagement, both with the CTSA network and other hubs, and the Bronx community and healthcare partners in an integrative paradigm with strategies developed in collaboration with community partners, investigators, and institutional leadership to improve population health; 4) advance life span, child health, and aging research across genders and special populations, by working with unique platforms for stakeholder-engaged research, patient safety and implementation science, the Montefiore Accountable Care Organization, and the New York City Practice-Based Research Network; and 5) innovate methods and processes that advance C/T sciences, and enhance quality, safety, and efficiency of C/T research. We will integrate the CTSA Trial Innovation Network into our ecosystem of multisite clinical trials, foster innovative methods for biomarker assays and biobanking for precision medicine, and leverage the CTSA Common Metrics Initiative to support our hub?s Evaluation and strategic management. Overall, the Einstein- Montefiore ICTR will fulfill NCATS?s tripartite mission to innovate, educate, and implement.

Public Health Relevance

The Einstein-Montefiore Institute for Clinical and Translational Research (ICTR) supports laboratory and clinical research investigators working to bring new treatments to the public more quickly, safely and efficiently with the overall goal of improving population health. The mission of the ICTR is also to train the next generation of clinical and translational research teams so that they develop the competencies to apply new knowledge and processes, as well as to expand collaborations with the community and healthcare partners.

Agency
National Institute of Health (NIH)
Institute
National Center for Advancing Translational Sciences (NCATS)
Type
Linked Specialized Center Cooperative Agreement (UL1)
Project #
5UL1TR002556-05
Application #
10112978
Study Section
Special Emphasis Panel (ZTR1)
Program Officer
Talbot, Bernard
Project Start
2018-03-22
Project End
2023-02-28
Budget Start
2021-03-01
Budget End
2022-02-28
Support Year
5
Fiscal Year
2021
Total Cost
Indirect Cost
Name
Albert Einstein College of Medicine
Department
Type
DUNS #
081266487
City
Bronx
State
NY
Country
United States
Zip Code
10461
George, Claudene J; Verghese, Joe; Izzetoglu, Meltem et al. (2018) The effect of polypharmacy on prefrontal cortex activation during single and dual task walking in community dwelling older adults. Pharmacol Res 139:113-119
Brodin, N Patrik; Tomé, Wolfgang A (2018) Revisiting the dose constraints for head and neck OARs in the current era of IMRT. Oral Oncol 86:8-18
Gonzalez, Cristina M; Garba, Ramya J; Liguori, Alyssa et al. (2018) How to Make or Break Implicit Bias Instruction: Implications for Curriculum Development. Acad Med 93:S74-S81
Rudolph, Bryan; Bjorklund, Nicole; Ovchinsky, Nadia et al. (2018) Methods to improve the noninvasive diagnosis and assessment of disease severity in children with suspected nonalcoholic fatty liver disease (NAFLD): Study design. Contemp Clin Trials 75:51-58
Veenstra, Mike; Byrd, Desiree A; Inglese, Matilde et al. (2018) CCR2 on Peripheral Blood CD14+CD16+ Monocytes Correlates with Neuronal Damage, HIV-Associated Neurocognitive Disorders, and Peripheral HIV DNA: reseeding of CNS reservoirs? J Neuroimmune Pharmacol :
Fuller, Anne; Messito, Mary Jo; Mendelsohn, Alan L et al. (2018) Prenatal Material Hardships and Infant Regulatory Capacity at 10 Months Old in Low-Income Hispanic Mother-Infant Pairs. Acad Pediatr 18:897-904
Callisaya, Michele L; Verghese, Joe (2018) The Association of Clinic-Based Mobility Tasks and Measures of Community Performance and Risk. PM R 10:704-711.e1
Salazar, Guadalupe; Tarwala, Geeta; Reznik, Marina (2018) School-based supervised therapy programs to improve asthma outcomes: current perspectives. J Asthma Allergy 11:205-215
Scott, Stacey B; Sliwinski, Martin J; Zawadzki, Matthew et al. (2018) A Coordinated Analysis of Variance in Affect in Daily Life. Assessment :1073191118799460
Taya, Michio; McHargue, Cody; Ricci, Zina J et al. (2018) Comparison of extracolonic findings and clinical outcomes in a screening and diagnostic CT colonography population. Abdom Radiol (NY) :

Showing the most recent 10 out of 33 publications